文献速递血栓与止血造血干细胞移植与细胞治疗

大出血与血栓形成对英国重症COVID-19接受VV-ECMO支持患者180天生存的影响:多中心观察性研究

Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study.
PubMed 文献 · Br J Haematol · 2021-10-07

该多中心观察性研究纳入英国四个中心152例接受VV-ECMO的重症COVID-19患者,评估大出血和血栓形成发生率及其与180天死亡率的关系。大出血、颅内出血和肺栓塞均与180天死亡风险升高独立相关。

要点

  • 大出血、颅内出血和肺栓塞均与180天死亡风险升高独立相关。

核心结论

  • 重症COVID-19接受VV-ECMO支持患者中,大出血、颅内出血和肺栓塞与180天死亡风险升高独立相关。

研究设计与样本

  • 多中心观察性研究,纳入英国四个中心2020年3月1日至5月31日连续152例≥18岁重症COVID-19接受VV-ECMO的患者。
  • 中位年龄47岁(范围23-65岁),男性占75%。

临床怎么用

  • 接受VV-ECMO的重症COVID-19患者需密切监测大出血和血栓事件,平衡抗凝治疗。
  • 颅内出血和肺栓塞事件提示预后不良,应加强相应筛查与防治。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bleeding and thrombosis are major complications in patients supported with extracorporeal membrane oxygenation (ECMO). In this multicentre observational study of 152 consecutive patients (≥18 years) with severe COVID-19 supported by veno-venous (VV) ECMO in four UK commissioned centres during the first wave of the COVID-19 pandemic (1 March to 31 May 2020), we assessed the incidence of major bleeding and thrombosis and their association with 180-day mortality. Median age (range) was 47 years (23-65) and 75% were male. Overall, the 180-day survival was 70·4% (107/152). The rate of major bleeding was 30·9% (47/152), of which intracranial bleeding (ICH) was 34% (16/47). There were 96 thrombotic events (63·1%) consisting of venous 44·7% [68/152 of which 66·2% were pulmonary embolism (PE)], arterial 18·6% (13/152) and ECMO circuit thrombosis 9·9% (15/152). In multivariate analysis, only raised lactate dehydrogenase (LDH) at the initiation of VV ECMO was associated with an increased risk of thrombosis [hazard ratio (HR) 1·92, 95% CI 1·21-3·03]. Major bleeding and ICH were associated with 3·87-fold (95% CI 2·10-7·23) and 5·97-fold [95% confidence interval (CI) 2·36-15·04] increased risk of mortality and PE with a 2·00-fold (95% CI1·09-3·56) risk of mortality. This highlights the difficult balancing act often encountered when managing coagulopathy in COVID-19 patients supported with ECMO.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Arachchillage DJ, Rajakaruna I, Scott I, et al. Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. Br J Haematol. 2021. PMID: 34622443. doi:10.1111/bjh.17870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。